Kiliçturgay S, Haberal M
Turkish Transplantation and Burn Foundation Hospital, Ankara.
Ren Fail. 1993;15(5):629-33. doi: 10.3109/08860229309069414.
Renal transplantation therapy performed for amyloid nephropathy is controversial because of the fatal effects of the disease. Amyloidosis is a relatively frequent disease and is generally associated with familial Mediterranean fever (FMF) in Turkey. Renal transplantation in the treatment of amyloid nephropathy started in January 1985. Till now, 18 (3.2%) renal transplantations have been performed on patients who had amyloid nephropathy. The mean follow-up period was 34.6 months. Fourteen renal grafts still function well (creatinine: 1-3.2 mg/dL). The overall 1-year patient and graft survival rates were 88.9% and 83.0%, respectively. These rates are not statistically different from renal transplantations done for other cases of renal failure. Therefore, patients with end-stage renal failure due to amyloidosis can be considered as appropriate candidates for renal transplantation.
由于淀粉样肾病的致命影响，针对该疾病进行的肾移植治疗存在争议。淀粉样变性是一种相对常见的疾病，在土耳其通常与家族性地中海热（FMF）相关。1985年1月开始采用肾移植治疗淀粉样肾病。截至目前，已对患有淀粉样肾病的患者进行了18例（3.2%）肾移植。平均随访期为34.6个月。14个肾移植仍功能良好（肌酐：1 - 3.2mg/dL）。总体1年患者和移植肾存活率分别为88.9%和83.0%。这些比率与因其他肾衰竭病例进行的肾移植在统计学上无差异。因此，因淀粉样变性导致终末期肾衰竭的患者可被视为肾移植的合适候选者。
